|
nasdaq:mlnt
|
1221548
|
Apr 28th, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 27th, 2024 11:41PM
|
Apr 27th, 2024 11:41PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 27th, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 26th, 2024 11:20PM
|
Apr 26th, 2024 11:20PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 26th, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 25th, 2024 11:28PM
|
Apr 26th, 2024 08:48AM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 25th, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 24th, 2024 11:22PM
|
Apr 25th, 2024 07:01PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 24th, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 23rd, 2024 11:29PM
|
Apr 24th, 2024 11:30AM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 23rd, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 22nd, 2024 11:11PM
|
Apr 23rd, 2024 05:03PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 22nd, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 21st, 2024 11:50PM
|
Apr 21st, 2024 11:50PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 21st, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 20th, 2024 11:47PM
|
Apr 20th, 2024 11:47PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 20th, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 19th, 2024 11:44PM
|
Apr 20th, 2024 05:19PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|
|
nasdaq:mlnt
|
1221548
|
Apr 19th, 2024 12:00AM
|
Cempra Pharmaceuticals
|
2.0K
|
12.00
|
Open
|
|
Apr 18th, 2024 11:51PM
|
Apr 18th, 2024 11:51PM
|
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
|
Open
|
|
Open
|
6320 Quadrangle Drive
|
Chapel Hill
|
NORTH CAROLINA
|
US
|
27517
|
|
Melinta
|
|
|